News & Updates

Edaravone appears to be safe and effective in the treatment of patients with ischaemic stroke, yielding improvements in activities of daily living and neurologic deficits in the short term, a study has found.

Among nonsmall cell lung cancer (NSCLC) patients with mutations spanning exons 18 to 21, combination treatment with amivantamab and lazertinib induces high rates of response, reports a study presented at the recent 2022 European Society for Medical Oncology Asia Congress (ESMO Asia 2022).

In patients with atopic dermatitis (AD), treatment with the IL-13 cytokine-targeting tralokinumab appears to directly or indirectly improves skin microbial dysbiosis, reports a new trial.

First-line treatment with alectinib appears to produce sustained clinical benefit in Asian patients with advanced, ALK-positive nonsmall cell lung cancer (NSCLC) through 5 years of follow-up, according to long-term data from the phase III ALESIA presented at the ESMO Asia Congress 2022.

Treatment with SCC244, a novel small molecule inhibitor of the enzyme MET kinase, appears to help overcome the resistance to tyrosine kinase inhibitors (TKI) mediated by MET amplification in nonsmall cell lung cancer (NSCLC), reports a new study presented at the recent 2022 European Society for Medical Oncology Asia Congress (ESMO Asia 2022).

The addition of radiation therapy to chemotherapy may be more detrimental than beneficial in patients with resectable stage III nonsmall‐cell lung cancer (NSCLC), being associated with a heightened risk of severe cardiac events, as shown in a study.